Does Nicotine Make You Poop? What It Does to the First Brain

A potent alkaloid can force a colon to empty once. It cannot rebuild whatever stopped that colon from emptying on its own.

I am Dr. Gurpreet Singh Padda, MD, MBA, MHP, and the video above closes The Angry Gut, written with Ami Michelle Grimes. Patients ask about this more often than clinicians admit, usually after a forum post about a vape and a reliable morning. So does nicotine make you poop? Sometimes, once, through a mechanism that is not the one a stalled bowel needs.

The first brain runs on acetylcholine

The nervous system in the gut wall is the first brain. The organ in the skull is the second, tethered to the first by the vagus. That first brain runs substantially on acetylcholine, and nicotine speaks the same chemical language, which is the whole reason a cigarette ever changed anyone’s bowel habits.

The human evidence is narrow and real. In fresh human colon, action potentials fired in 51 neurons drawn from 20 myenteric ganglia across 19 patients, in bursts of 2 to 23 potentials at about 5.3 Hz. The ceiling is printed alongside it: only about 8% of human myenteric neurons responded at all, a figure the authors themselves call low. A genuine signal, in a minority of cells.

Two receptor subtypes do two different jobs, and separating them settles most of the apparent contradictions. Fast transmission between enteric neurons runs mainly through the alpha-3-beta-4 subtype, and blocking it drops evoked responses. The alpha-7 subtype sits on monocytes and macrophages instead, where acetylcholine switches off release of TNF, one of the body’s loudest inflammatory signals. Vagal stimulation suppresses TNF in normal mice and fails completely in alpha-7-deficient ones. The subunit mapping is rodent work and deserves to be read as rodent work. The immune receptor is the one behind the reflex in the chapter on the vagus nerve.

One evacuation wave is real. The housekeeping sweep is not.

Two motility claims get made about this molecule, and they do not stand or fall together.

The evacuation claim holds up in people. In healthy subjects a high dose produced transient high-amplitude propagated contractions and faster colonic transit. That contraction is mass peristalsis, the wave that empties a colon and the event that comes just before a bowel movement. It was not inferred from a receptor map. It was recorded in a human colon after a cholinergic agonist.

The housekeeping claim does not hold. The migrating motor complex is a separate cycle in a separate compartment, the fasting sweep through the stomach and small bowel. A patch-equivalent dose decreased antral motor complex periodicity and scrambled the gastric pacemaker, with tachygastria in nonsmokers rising from 2% to 16% of recording time. That instability normalized with indomethacin, which makes it prostaglandin-dependent, and in smokers the tracing did not change. Two weeks of wearing a patch moved nothing anyone could measure: gastric emptying, small-bowel transit and orocecal transit all stayed put. The same experiment did detect drug-induced barrier injury, so the null was not a dull instrument.

Then somebody randomized the prokinetic idea. Forty patients after elective colorectal surgery for cancer chewed either 2 mg nicotine gum or ordinary gum. Six in each group developed a prolonged ileus, and time to the primary endpoint ran 4.50 days on nicotine against 3.50 on plain gum. Both medians favored the plain gum. No nicotinic agonist has ever been developed as a gut prokinetic, and the class that has is serotonergic.

Dose and site decide the direction

Three human results stop fighting once they are sorted by dose. A low dose placed inside the bowel lowered smooth muscle tone in all 17 subjects, and reduced or abolished the large contractions in the patients who had colitis, while saline did nothing. A low systemic dose, the kind a patch delivers, reduced colonic compliance in healthy subjects and left motor function untouched in colitis patients. A large acute dose brought on the propagating waves and quicker transit, followed by a relaxed descending colon and less phasic activity.

Small doses quiet a distal colon, which is what an inflamed rectum needs. A large acute dose produces a propagating wave, which is what an obstructed one needs. There is an uncomfortable corollary for anyone judging a remedy by how they feel: when urgency and diarrhea settle, part of what is being enjoyed may be an anti-kinetic effect rather than repair. Feeling better and being better are two separate measurements.

Why a pain practice cares about receptors in the bowel wall

Three reasons, and only the first is obvious. A distended, obstructed bowel generates pain of its own, and the receptor that produces mass peristalsis sits in the wall of the organ producing it. Second, alpha-7 on macrophages is a brake on TNF, so the receptor family that moves the bowel also governs how loudly its immune tissue signals, and the flora layered on top of that conversation are the subject of the pathways running from gut microbes to mood.

Third, and least discussed, the reason the question stays open is economic. This is an off-patent alkaloid that shares a surname with tobacco. A question with no sponsor stays unanswered, and that is why the one preparation that might settle the argument has never been given to a human being.

Four hurdles, and a harm further up the tube

Anyone weighing this deserves the objections first. Tachyphylaxis leads, because a drug that quits working in two weeks makes a poor chronic therapy. The single direct human observation runs the other way, since the nicotinic response in human myenteric neurons did not fade between a first and a second application, but that is two stimulations in a tissue bath, not two months in a patient. Mucosal irritation at an already inflamed site has no long-term rectal safety data behind it. Systemic toxicity is reduced by local delivery and never abolished: peak plasma nicotine after an enema arrives at 44 to 50 minutes, and of the 14 adverse events recorded, 11 arrived 30 to 105 minutes later, most of them at the 9 mg dose. Blood-pressure spikes and a racing heart belong to the molecule, not to the smoke. Dependency does not leave when combustion does.

The named harm sits higher. Transdermal nicotine lowers pressure in the valve at the bottom of the esophagus much as smoking does, and pH monitoring confirms the extra acid exposure. For a patient who already refluxes, that is a specific argument against the patch.

One detail complicates the toxicity story in a useful direction. In the liquid enema pilot, adverse events occurred in 4 of 10 patients even though serum nicotine was low or undetectable, and the authors judged them unrelated to the drug. If a patient feels ill on a dose that never reached her blood, some of what gets filed as nicotine toxicity is not nicotine.

Rescue is not repair

The hardest argument here is the one I make against myself. Emptying a bowel by force with an alkaloid addresses the downstream failure and leaves the cause upstream untouched. If the vagal signal is damaged, no nicotinic agonist repairs a nerve. If the flora that regulate transit have been flattened, no receptor stimulus replaces a community, which is the case laid out in the chapter on the flora. If the enteric nervous system is injured, depolarizing whatever neurons remain restores nothing.

Rescue still earns a place. In our practice a procedure is a bridge, legitimate for exactly as long as something waits on the far side, and a drug that forces an evacuation answers to the same test. A preparation that ended five days of nothing would be worth having. It would never be a treatment for why the bowel stopped.

So the plan has to reach the terrain. The first brain answers to being fed and tended, then left alone, and it does not answer to a molecule bought online. There is no product for this, no dose established outside a trial, and nothing here to improvise with at home. Do not start, stop or change any medication on your own; take it to the physician who prescribes for you. The Chapter 32 Deep Dive lists every study named here with its population, its numbers and what each one does not show, along with questions worth asking at your next visit, and the previous chapter in this series sets up the argument this one closes.

Frequently asked questions

Does nicotine make you poop?

It can, once. In healthy volunteers a high dose produced high-amplitude propagated contractions, the mass peristalsis wave that comes before a bowel movement, together with faster colonic transit. The effect was acute and transient, followed by relaxation of the descending colon and less phasic activity. Nothing in the human record turns that single wave into a sustained treatment. Resident bacteria shape what the colon does day to day.

Can nicotine restart a bowel that has stopped?

No human trial supports it. Nicotine gum tested after colorectal surgery was safe and useless, with time to the primary endpoint running 4.50 days against 3.50 on plain gum. Upstream, a patch-level dose disorganized the stomach’s pacemaker rather than organizing it, and two weeks of a patch changed neither gastric emptying nor transit. Pain-sensing nerves in the gut have their own role in inflammation.

Is a nicotine patch a problem if I have reflux?

It is a fair concern. Transdermal nicotine lowers the pressure in the valve at the bottom of the esophagus much as smoking does, and pH monitoring confirms additional acid exposure. That makes the patch a poor fit for someone who already refluxes, and it is a decision for the physician managing both problems. Some medications quietly worsen the problem they treat.

Why would a pain clinic care about a gut receptor?

Because the alpha-7 subtype sits on monocytes and macrophages, where acetylcholine shuts off TNF release. A receptor family that governs inflammatory signaling in the gut wall works on the same terrain that keeps a nervous system sensitized. Vagal stimulation suppresses TNF in normal mice and fails in alpha-7-deficient ones, which is mouse work and reads as mouse work. Why we treat the inflammation before the joint.

Is there a nicotine suppository for a stalled gut?

No published trial of a nicotine suppository exists, in any indication. One group built formulations and measured release across a cell monolayer, and none of it ever entered a living gut. That is an absence of evidence, not a negative result, and it is a reason for a proper trial rather than an experiment on yourself. Pain rarely moves when only one input is pushed.

Sources

1. Coulie, B., Camilleri, M., Bharucha, A. E., Sandborn, W. J., & Burton, D. (2001). Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects.. Alimentary Pharmacology & Therapeutics, 15(5), 653-663. https://doi.org/10.1046/j.1365-2036.2001.00959.x
2. Elfers, K., Sehnert, A. S., Wagner, A., Zwirner, U., Linge, H., Kulik, U., Poehnert, D., Winny, M., Gundert, B., Aselmann, H., & Mazzuoli-Weber, G. (2024). Functional and structural investigation of myenteric neurons in the human colon.. Gastro Hep Advances, 4(1), 100537. https://doi.org/10.1016/j.gastha.2024.08.016
3. Green, J. T., McKirdy, H. C., Rhodes, J., Thomas, G. A., & Evans, B. K. (1999). Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel.. European Journal of Gastroenterology & Hepatology, 11(11), 1299-1304. https://doi.org/10.1097/00042737-199911000-00020
4. Ingram, J. R., Routledge, P., Rhodes, J., Marshall, R. W., Buss, D. C., Evans, B. K., Feyerabend, C., & Thomas, G. A. O. (2004). Nicotine enemas for treatment of ulcerative colitis: A study of the pharmacokinetics and adverse events associated with three doses of nicotine. Alimentary Pharmacology & Therapeutics, 20(8), 859-65. https://doi.org/10.1111/j.1365-2036.2004.02199.x
5. Kohagen, K. R., Kim, M. S., McDonnell, W. M., Chey, W. D., Owyang, C., & Hasler, W. L. (1996). Nicotine effects on prostaglandin-dependent gastric slow wave rhythmicity and antral motility in nonsmokers and smokers.. Gastroenterology, 110(1), 3-11. https://doi.org/10.1053/gast.1996.v110.pm8536873
6. Lambrichts, D. P. V., Boersema, G. S. A., Tas, B., Wu, Z., Vrijland, W. W., Kleinrensink, G.-J., Jeekel, J., Lange, J. F., & Menon, A. G. (2017). Nicotine chewing gum for the prevention of postoperative ileus after colorectal surgery: a multicenter, double-blind, randomised, controlled pilot study.. International Journal of Colorectal Disease, 32(9), 1267-1275. https://doi.org/10.1007/s00384-017-2839-z
7. Pandolfino, J. E., & Kahrilas, P. J. (2000). Smoking and gastro-oesophageal reflux disease.. European Journal of Gastroenterology & Hepatology, 12(8), 837-842. https://doi.org/10.1097/00042737-200012080-00002
8. Suenaert, P., Bulteel, V., Den Hond, E., Geypens, B., Monsuur, F., Luypaerts, A., Ghoos, Y., & Rutgeerts, P. (2003). In vivo influence of nicotine on human basal and NSAID-induced gut barrier function.. Scandinavian Journal of Gastroenterology, 38(4), 399-408. https://doi.org/10.1080/00365520310000834
9. Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C. J., & Tracey, K. J. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.. Nature, 421(6921), 384-388. https://doi.org/10.1038/nature01339

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 32 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP